Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30486882 | 1.00 | MTNR1A (0.50) | MTNR1ANTRK1GABRG2GABRB3GABRA5 | |
| SCHEMBL21979491 | 0.82 | MTNR1A (0.55) | MTNR1ANTRK1GRM5SPRSMN1; SMN2 | |
| SCHEMBL30486887 | 0.75 | MTNR1A (0.38) | MTNR1AGABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL21979507 | 0.75 | MTNR1A (0.38) | MTNR1AGABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL24342347 | 0.75 | HSD17B10 (0.37) | MTNR1ANTRK1GABRG2GABRB3GABRA5 | |
| SCHEMBL30495357 | 0.75 | HSD17B10 (0.37) | MTNR1ANTRK1GABRG2GABRB3GABRA5 | |
| SCHEMBL29376883 | 0.75 | ELANE (0.46) | NR4A2BRD4 | |
| SCHEMBL17995257 | 0.75 | ELANE (0.46) | NR4A2BRD4 | |
| SCHEMBL24342426 | 0.71 | MAPT (0.37) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL23612026 | 0.70 | NR4A2 (0.46) | MTNR1ANR4A2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-12428418-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3624796-B1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250034137-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12065439-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| CN-113660931-A | Arylaniline and heteroarylaniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113645964-A | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy | 恩福莱克逊治疗有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| CN-111065393-A | Pyrrolopyridine-anilines for the treatment of skin diseases | 恩福莱克逊治疗有限公司 | 2020-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, PRKDC, MAPK1 | MTNR1A 2052/4885NTRK1 332/4885GABRG2 4380/4885 |
| US-20250034137-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MTNR1A 1585/4885NTRK1 1382/4885GABRG2 4696/4885 |
| US-12065439-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MTNR1A 1585/4885NTRK1 1382/4885GABRG2 4696/4885 |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MTNR1A 1666/4885NTRK1 1299/4885GABRG2 4694/4885 |
| US-12428418-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MTNR1A 1585/4885NTRK1 1382/4885GABRG2 4696/4885 |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NCOA3, TYR, CYP3A43 | MTNR1A 180/4885NTRK1 1568/4885GABRG2 3881/4885 |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MTNR1A 1623/4885NTRK1 1295/4885GABRG2 4685/4885 |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MTNR1A 1585/4885NTRK1 1382/4885GABRG2 4696/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | MTNR1A 163/4885NTRK1 1137/4885GABRG2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.